feedback

Course Director

Ian W. Flinn, MD, PhD
Ian W. Flinn, MD, PhD

Sarah Cannon Research Institute
Nashville, Tennessee

Accredited by

Penn State College of Medicine / Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CE
Credit Amount:1.0 Credits
Release Date:2017-May-02
Expiration Date:2018-May-01
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, an expert in the management of non-Hodgkin lymphomas discusses the evolving role of novel agent classes, including BTK inhibitors, next-generation antibodies, Bcl-2 inhibitors, and immunomodulators, and provides perspectives on the optimal application of these agents for patients with B-cell NHL.

Upon completion of this activity, participants will be able to:

  • Summarize current evidence and guidelines on the role of novel agent classes and next-generation therapeutics in the management of B-cell malignancies such as CLL, MCL, MZL, FL, and DLBCL
  • Integrate novel therapeutics into the management of newly diagnosed and relapsed/refractory patients with indolent or aggressive non-Hodgkin lymphomas (NHLs)
  • Utilize disease- and patient-related factors such as age, cytogenetics, and others to personalize therapy in patients with B-cell NHLs
  • Manage safety considerations in patients with B-cell malignancies on therapy with newer agents, including BTK inhibitors, next-generation antibodies, Bcl-2 inhibitors, immunomodulators, or other novel therapies

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, and advanced practice nurses involved in the management of patients with non-Hodgkin lymphoma.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of non-Hodgkin lymphomas.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 02, 2017 - May 01, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine and Medical Learning Institute, Inc. has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director

Ian W. Flinn, MD, PhD
Director, Lymphoma/CLL Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Acerta Pharma; Agios, Inc.; BeiGene; Celgene Corporation; Constellation Pharmaceuticals; Curis, Inc.; Forty Seven Inc.; Genentech, Inc.; Gilead; ImmunoGen, Inc.; Janssen Pharmaceuticals, Inc.; Kite Pharma; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Seattle Genetics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; TG Therapeutics, Inc.; Trillium Therapeutics Inc.; and Verastem Inc. (All research funding goes to institution.)

Ian W. Flinn, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Anti-CD20 monoclonal antibodies, BCR inhibitors, immunomodulatory agents, Bcl2 inhibitors, and CAR T-cell therapy in B-cell lymphomas.

Nurse Reviewer

Pamela Ash, RN, MSN, CBCN
Supportive Care Nurse Clinician
Mary Babb Randolph Cancer Center Clinic
West Virginia University
Morgantown, West Virginia

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Disclaimer

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6092-17-T.

Nurses

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

Providership

This CME/CE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; this activity is also co-provided by Medical Learning Institute, Inc.

Support

This activity is supported by independent educational grants from AbbVie, Celgene Corporation and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.